Evaluation of EuroFlow minimal residual disease measurement and donor chimerism monitoring following tandem auto-allogeneic transplantation for multiple myeloma-Reference-Cited by-同舟云学术

Evaluation of EuroFlow minimal residual disease measurement and donor chimerism monitoring following tandem auto-allogeneic transplantation for multiple myeloma

Published:2020-12-01 Issue:5 Volume:56 Page:1116-1125
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Tan Joanne L. C.^ORCID,Das Tongted^ORCID,Kliman David^ORCID,Muirhead Jenny,Gorniak Malgorzata,Kalff Anna,Walker Patricia,Spencer Andrew

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/s41409-020-01148-y.pdf

Reference30 articles.

1. Fonseca R, Abouzaid S, Bonafede M, Cai Q, Parikh K, Cosler L, et al. Trends in overall survival and costs of multiple myeloma, 2000–2014. Leukemia. 2017;31:1915–21.

2. Turesson I, Bjorkholm M, Blimark CH, Kristinsson S, Velez R, Landgren O. Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival. Eur J Haematol. 2018;101:237–44.

3. Aggarwal M, Agrawal N, Yadav N, Verma P, Ahmed R, Mehta P, et al. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma. Ann Hematol. 2018;97:1869–77.

4. Schönland SO, Iacobelli S, Koster L, Blaise D, Potter M, Cornelissen J, et al. Comparison of different upfront transplant strategies in multiple myeloma - a large registry study from chronic malignancies working party of EBMT. Blood 2019;134(Supplement_1):324. https://doi.org/10.1182/blood-2019-128795.

5. annual data summary «ABMTRR. http://www.abmtrr.org/index.php/annual-data-summary/. Accessed 28 Mar 2020.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years;Frontiers in Oncology;2024-07-31

2. Cellular Immunotherapies for Multiple Myeloma: Current Status, Challenges, and Future Directions;Oncology and Therapy;2022-02-01

3. Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study;Bone Marrow Transplantation;2021-11-29